ClinicalTrials.gg
RecruitingNCT06528262ENAVO-AFUpdated May 12, 2026

Effect of Enavogliflozin on Recurrence of Atrial Fibrillation After Catheter Ablation

A Phase 4 interventional study of Enavogliflozin and Placebo in Atrial Fibrillation, sponsored by Yonsei University. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 84 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Yonsei University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
19 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Atrial Fibrillation by Yonsei University — 25 open to participants now, 26 under way, none of them phase 3. Atrial Fibrillation · Yonsei University.

Planned enrollment
14th of 42
390 · median 259
Started
2025
with 9 others
Phase 4
7 of 52
3 open now
Primary completion
2027-05
later than 8 of 25 live
Registered
38th of 52
by date

Among the 52 studies in Atrial Fibrillation by Yonsei University, this one is the 14th largest by planned enrollment of the 42 interventional ones that give a count, is one of 10 that started in 2025, is one of 7 in phase 4, reaches primary completion later than 8 of the 25 other live ones, and was the 38th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

25 of the 52 studies in Atrial Fibrillation by Yonsei University are open now, in 1 country. Recruiting first, the newest first:

19 more — sign in →

By country, each count listing its studies:

All 25 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 19 Years to 84 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Atrial Fibrillation by Yonsei University, or all of them as a file.
02

Study summary

Objective: The purpose of this study is to determine if there is a difference in the recurrence rate of atrial fibrillation (AF) between a group of patients with AF and heart failure undergoing catheter ablation who are administered the SGLT2 inhibitor, Enavogliflozin, and a control group (placebo group). This study aims to investigate whether SGLT2 inhibitors can prevent the recurrence of AF after the procedure.

Background: AF is the most common arrhythmia requiring treatment, with its prevalence increasing with age. In the US, AF affected 5.2 million people in 2010 and is projected to reach 12.1 million by 2030. In South Korea, prevalence rose from 0.73% in 2006 to 1.53% in 2015. Early-stage AF patients benefit more from rhythm control therapy than from heart rate control alone, as shown by the 2020 EAST-AFNET-4 trial, which reported a 21% reduction in adverse cardiovascular events. Catheter ablation for rhythm control significantly reduces AF recurrence compared to antiarrhythmic drugs, leading to more patients undergoing this procedure. AF and heart failure often coexist, forming a vicious cycle that exacerbates both conditions and leads to poorer outcomes. They share common risk factors like hypertension, diabetes, ischemic heart disease, and valvular disease. Heart failure increases left atrial filling pressure and alters intracellular calcium levels, raising AF risk. Further research is needed on their pathophysiological link. SGLT2 inhibitors reduce glucose reabsorption in the kidneys to control hyperglycemia in diabetics and have been shown in large studies (DAPA-HF, EMPEROR-Reduced) to significantly reduce heart failure worsening and cardiovascular mortality, regardless of diabetes status. These benefits were seen in both HFrEF and HFpEF. In the DAPA-HF trial, 55% of participants were non-diabetic, and reductions in heart failure worsening or cardiovascular death were similar between those with and without diabetes (25% vs. 27%). Adverse events, including volume depletion and renal function decline, were not significantly different between diabetic and non-diabetic patients, and no hypoglycemia or ketoacidosis occurred in non-diabetic patients. Recent studies show SGLT2 inhibitors reduce AF incidence and benefit heart failure. A sub-analysis of the DECLARE-TIMI 58 trial reported a 19% reduction in AF risk among diabetic patients with SGLT2 inhibitors. Meta-analyses by Okunrintemi and Zheng showed an 18% reduction in AF risk irrespective of diabetes status. Interest is growing in the relationship between SGLT2 inhibitors and AF recurrence post-catheter ablation. Luo et al. reported a nearly 39% reduction in AF recurrence post-ablation with dapagliflozin in diabetic patients. Kishima et al. found a 49% reduction in AF recurrence post-ablation with SGLT2 inhibitors versus DPP-IV inhibitors in a small prospective randomized study. However, most studies were retrospective, sub-analyses, or small-scale studies limited to diabetics. Prospective randomized studies involving AF patients regardless of diabetes status are urgently needed for validation.

Read the detailed description

Study Design Overview:

  • Single-center, prospective, randomized controlled, double-blind study.
  • Patients who consent will be randomly assigned to either the intervention or control group.
  • The intervention group will receive Enavogliflozin 0.3 mg once daily. The control group will receive a placebo in the same form.
  • The administration period will be 360±30 days, targeting patients hospitalized for AF catheter ablation at Severance Hospital or those who have undergone the procedure within the past three months.
  • Target participants: 195 in the experimental group (SGLT2 inhibitor group), 195 in the control group (placebo group), totaling 390 participants.
  • Regular standard ECG examinations will be conducted at 1, 3, 6, and 12 months post-procedure, and as needed based on symptoms.
  • Wearable ECG patch (8-14 days) tests will be conducted at 3, 6, and 12 months follow-up visits.
  • Comparison of AF recurrence rates from 3 months to 1 year post-catheter ablation.
  • Comparison of AF burden from catheter ablation up to 1 year post-procedure.
03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
19 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 19 to under 85
  2. Patients who consent to participate in the study and can be followed up during the study
  3. Patients with AF and heart failure who have undergone atrial fibrillation catheter ablation within the last three months or are scheduled to undergo the procedure

Exclusion criteria

Exclusion Criteria:

  1. Under 19 or over 85 years old
  2. Patients who have participated in another clinical trial within the last three months
  3. of less than one year
  4. Pregnant or breastfeeding women
  5. Currently being treated with an SGLT-2 inhibitor
  6. Three or more urinary or genital infections within the last year
  7. Uncontrolled hypertension: systolic blood pressure ≥ 180mmHg or diastolic blood pressure ≥ 110mmHg
  8. Systolic blood pressure \< 90mmHg
  9. Acute cardiovascular event within the last 12 weeks
  10. Severe valvular disease or presence of artificial valves
  11. Renal impairment ( CKD-EPI \< 60 ml/min/1.73m²)
  12. Clinically confirmed liver dysfunction
  13. Uncontrolled thyroid dysfunction
  14. Patients with active cancer (including those undergoing treatment) or history of cancer within the last five years at the time of screening; however, borderline cancers are not excluded if successfully treated and recurrence-free for 2-3 years.
  15. Continuous use of oral prednisolone at 10mg/day or equivalent, or higher doses of , within the last month
  16. Patients with or history of hypersensitivity to the active or inactive ingredients of this drug
  17. Patients with type 1 diabetes or diabetic ketoacidosis
  18. History of alcohol or substance abuse
  19. Women of who do not agree to use adequate during the clinical trial period
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
390 participants (estimated)

Study arms

  • Experimental
    Enavogliflozin

    Enavogliflozin as a study group

    Drug: Enavogliflozin

  • Placebo comparator
    Placebo

    Placebo as a comparison group

    Drug: Placebo

Interventions

  • Patients hospitalized at Severance Hospital for atrial fibrillation catheter ablation, or those who had the procedure within the last three months, will be randomly assigned to receive either 0.3 mg of enavogliflozin once daily or a placebo for 360±30 days

  • DrugPlacebo

    Patients hospitalized at Severance Hospital for atrial fibrillation catheter ablation, or those who had the procedure within the last three months, will be randomly assigned to receive either 0.3 mg of enavogliflozin once daily or a placebo for 360±30 days

06

What researchers measure

Primary outcomes

  1. Difference in the recurrence rate of atrial fibrillation (AF) between the experimental group (enavogliflozin group) and the control group (placebo group) from 3 months to 1 year after catheter ablation

    In subjects who have completed 12 months of follow-up or experienced AF recurrence, the difference in AF recurrence rates between the enavogliflozin group and the placebo group from 3 months to 1 year after catheter ablation will be investigated. AF recurrence is defined as atrial tachycardia/flutter/fibrillation lasting more than 30 seconds, as confirmed by ECG or Holter monitoring. Recurrences within the first 3 months post-procedure are considered part of the blanking period and are not included in the evaluation.

    Time frame: 12 months after catheter ablation

Secondary outcomes

  1. Difference in total AF burden (%) confirmed by Holter (wearable patch ECG) monitoring between the experimental group (enavogliflozin group) and the control group (placebo group) from 3 months to 1 year after catheter ablation

    Definition of total AF burden (%): Duration of the longest AF episode Number of AF episodes/total Holter monitoring period Time in AF/total Holter monitoring period

    Time frame: At 3, 6, 12 months after catheter ablation

  2. Difference in time to first AF recurrence between the experimental group (enavogliflozin group) and the control group (placebo group) from 3 months to 1 year after catheter ablation

    Time frame: 12 months after catheter ablation

  3. Difference in the heart failure hospitalization rate after catheter ablation between the experimental group (enavogliflozin group) and the control group (placebo group)

    Time frame: 12 months after catheter ablation

  4. The group difference in the AF symptom score (mEHRA) between baseline and 12 months after catheter ablation with enavogliflozin or placebo

    Time frame: Baseline and 12 months after catheter ablation

  5. The group difference in metabolic parameters, including glycated hemoglobin (HbA1c), body weight, insulin resistance (HOMA-IR), ketone bodies, and fatty liver index, between baseline and 12 months after catheter ablation with enavogliflozin or placebo

    Time frame: Baseline and 12 months after catheter ablation

  6. The group difference in serum NT-proBNP levels between baseline and 12 months after catheter ablation with enavogliflozin or placebo

    Time frame: Baseline and 12 months after catheter ablation

  7. Difference in adverse events, including hypoglycemia, diabetic ketoacidosis, and genitourinary infection rates, after catheter ablation between the experimental group (enavogliflozin group) and the control group (placebo group)

    Time frame: 12 months after catheter ablation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for May 2027, 25 months after the start.

Of 130 non-industry phase 4 interventional studies under Atrial Fibrillation, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's planned 25 months is below that.

Counting every sponsor, half of 142 studies reached it within 48 months; a quarter within 27 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2024
First posted
Jul 30, 2024
StartActual
Apr 3, 2025
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06528262
Lead sponsor
Yonsei University
Responsible party
Sponsor
First posted
Jul 30, 2024
Start date
Apr 3, 2025
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
May 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enavogliflozin

Start the discussion